ReviewCellular and molecular life sciences : CMLS2020
Revisiting cellular immune response to oncogenic Marek's disease virus: the rising of avian T-cell immunity.
Review in Cellular and molecular life sciences : CMLS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Evaluation of a multiantigen mRNA vaccine against EEHV1A in Asian elephants.Journal of virology · 2026Article
- First evidence of clinical protection from an EEHV1A mRNA vaccine in naturally infected juvenile elephants.Journal of virology · 2026Article
- A recombinant Marek's disease vaccine candidate provides complete protection against infectious bursal disease virus and H9 subtype avian influenza virus in chickens.Journal of virology · 2025Article
- Effect of MHC Haplotype on Mortality Due to Marek's Disease in Commercial Laying Hens.Animals : an open access journal from MDPI · 2025Article
- Nanoparticle-Based Antiviral Vaccines for Chickens: Recent Advances and Future Perspectives.Transboundary and emerging diseases · 2025Review
- Marek's disease: A global challenge to poultry health and productivity.Open veterinary journal · 2025Review
- Article
- Immune escape of avian oncogenic Marek's disease herpesvirus and antagonistic host immune responses.NPJ vaccines · 2024Review
- Co-administration of chicken IL-2 alleviates clinical signs and replication of the ILTV chicken embryo origin vaccine by pre-activating natural killer cells and cytotoxic T lymphocytes.Journal of virology · 2023Article
- The immune cell landscape and response of Marek's disease resistant and susceptible chickens infected with Marek's disease virus.Scientific reports · 2023Article
- The Role of Dendritic Cells in the Host Response to Marek's Disease Virus (MDV) as Shown by Transcriptomic Analysis of Susceptible and Resistant Birds.Pathogens (Basel, Switzerland) · 2022Article
- Integrated time-series transcriptomic and metabolomic analyses reveal different inflammatory and adaptive immune responses contributing to host resistance to PRRSV.Frontiers in immunology · 2022Article
- Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice.PloS one · 2022Article
- Article
- Article
- An Anti-Tumor Vaccine Against Marek's Disease Virus Induces Differential Activation and Memory Response of γδ T Cells and CD8 T Cells in Chickens.Frontiers in immunology · 2021Article
- The Evaluation of Cellular Immunity to Avian Viral Diseases: Methods, Applications, and Challenges.Frontiers in microbiology · 2021Review
- Article
- Morphological and Immunohistochemical Examination of Lymphoproliferative Lesions Caused by Marek's Disease Virus in Breeder Chickens.Animals : an open access journal from MDPI · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Marek's disease virus (MDV) is a highly oncogenic alphaherpesvirus that causes deadly T-cell lymphomas and serves as a natural virus-induced tumor model in chickens. Although Marek's disease (MD) is well controlled by current vaccines, the evolution of MDV field viruses towards increasing virulence is concerning as a better vaccine to combat very virulent plus MDV is still lacking. Our understanding of molecular and cellular immunity to MDV and its immunopathogenesis has significantly improved, but those findings about cellular immunity to MDV are largely out-of-date, hampering the development of more effective vaccines against MD. T-cell-mediated cellular immunity was thought to be of paramount importance against MDV. However, MDV also infects macrophages, B cells and T cells, leading to immunosuppression and T-cell lymphoma. Additionally, there is limited information about how uninfected immune cells respond to MDV infection or vaccination, specifically, the mechanisms by which T cells are activated and recognize MDV antigens and how the function and properties of activated T cells correlate with immune protection against MDV or MD tumor. The current review revisits the roles of each immune cell subset and its effector mechanisms in the host immune response to MDV infection or vaccination from the point of view of comparative immunology. We particularly emphasize areas of research requiring further investigation and provide useful information for rational design and development of novel MDV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.